Related Experiment Videos
Radiotherapy of T4 bladder carcinoma
Summary
Radiotherapy for advanced bladder cancer (T4NXMO) showed a 16% 5-year survival. Combining radiotherapy with chemotherapy (5-FUra) significantly improved 2-year survival, suggesting new treatment regimens are needed.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Oncology
Background:
- Bladder carcinoma, specifically T4NXMO stage, presents a significant therapeutic challenge.
- Limited survival rates are observed with current treatment modalities for advanced bladder cancer.
Purpose of the Study:
- To evaluate the survival outcomes of irradiated patients with T4NXMO bladder carcinoma.
- To assess the impact of combined radiotherapy and chemotherapy on survival.
- To identify prognostic factors in this patient cohort.
Main Methods:
- Retrospective analysis of 159 patients with T4NXMO bladder carcinoma treated with radiotherapy.
- Evaluation of prognostic parameters including tumor stage (T4a) and performance status.
- Assessment of survival rates at 2 and 5 years for different treatment combinations.
Main Results:
- A 16% 5-year crude survival rate was observed in the irradiated patient group.
- Tumor stage T4a and good performance status were identified as significant prognostic factors.
- The combination of radiotherapy with weekly 5-fluorouracil (5-FUra) injections demonstrated a significant increase in 2-year survival.
Conclusions:
- Combined radiotherapy and chemotherapy (5-FUra) show promise for improving survival in T4NXMO bladder carcinoma.
- Further development of novel combined radiotherapy/chemotherapy regimens is warranted.
- Prospective studies are needed to evaluate the palliative effect of radiotherapy compared to other treatments.